CA2536048A1 - Microparticules contenant l'antagoniste de cgrp 1-[n2-[3,5-dibromo-n-[[4-(3,4-dihydro-2(1h)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl)-piperazine, procede de production desdites particules ainsi que leur utilisation en tant que poudre d'inhalation - Google Patents

Microparticules contenant l'antagoniste de cgrp 1-[n2-[3,5-dibromo-n-[[4-(3,4-dihydro-2(1h)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl)-piperazine, procede de production desdites particules ainsi que leur utilisation en tant que poudre d'inhalation Download PDF

Info

Publication number
CA2536048A1
CA2536048A1 CA002536048A CA2536048A CA2536048A1 CA 2536048 A1 CA2536048 A1 CA 2536048A1 CA 002536048 A CA002536048 A CA 002536048A CA 2536048 A CA2536048 A CA 2536048A CA 2536048 A1 CA2536048 A1 CA 2536048A1
Authority
CA
Canada
Prior art keywords
active substance
excipient
excipients
drying gas
pyridinyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002536048A
Other languages
English (en)
Inventor
Michael Trunk
Claudius Weiler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International Gmbh
Michael Trunk
Claudius Weiler
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh, Michael Trunk, Claudius Weiler filed Critical Boehringer Ingelheim International Gmbh
Publication of CA2536048A1 publication Critical patent/CA2536048A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
CA002536048A 2003-08-18 2004-08-12 Microparticules contenant l'antagoniste de cgrp 1-[n2-[3,5-dibromo-n-[[4-(3,4-dihydro-2(1h)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl)-piperazine, procede de production desdites particules ainsi que leur utilisation en tant que poudre d'inhalation Abandoned CA2536048A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10338399A DE10338399A1 (de) 2003-08-18 2003-08-18 Mikropartikel, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-Iysyl]-4-(4-pyridinyl)-piperazin, Verfahren zu deren Herstellung sowie deren Verwendung als Inhalaltionspulver
DEDE10338399.9 2003-08-18
PCT/EP2004/009013 WO2005018609A1 (fr) 2003-08-18 2004-08-12 Microparticules contenant l'antagoniste de cgrp 1-[n2-[3,5-dibromo-n-[[4-(3,4-dihydro-2(1h)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl)-piperazine, procede de production desdites particules ainsi que leur utilisation en tant que poudre d'inhalation

Publications (1)

Publication Number Publication Date
CA2536048A1 true CA2536048A1 (fr) 2005-03-03

Family

ID=34201779

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002536048A Abandoned CA2536048A1 (fr) 2003-08-18 2004-08-12 Microparticules contenant l'antagoniste de cgrp 1-[n2-[3,5-dibromo-n-[[4-(3,4-dihydro-2(1h)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl)-piperazine, procede de production desdites particules ainsi que leur utilisation en tant que poudre d'inhalation

Country Status (6)

Country Link
EP (1) EP1658051A1 (fr)
JP (1) JP2007502790A (fr)
CA (1) CA2536048A1 (fr)
DE (1) DE10338399A1 (fr)
UY (1) UY28474A1 (fr)
WO (1) WO2005018609A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10338402A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sprühgetrocknetes, amorphes BIBN 4096, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum
DE10338407A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Inhalationspulver enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1242211A (en) * 1967-08-08 1971-08-11 Fisons Pharmaceuticals Ltd Pharmaceutical composition
DE19937304C2 (de) * 1999-08-10 2003-08-21 Boehringer Ingelheim Pharma Verwendung von CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen
WO2001056581A1 (fr) * 2000-02-04 2001-08-09 Kissei Pharmaceutical Co., Ltd. Preparation en poudre pour inhalation et inhalateur de poudre contenant cette preparation
GB0014851D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
DE10139410A1 (de) * 2001-08-17 2003-02-27 Boehringer Ingelheim Pharma Verwendung von BIBN4096 in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne
DE10206770A1 (de) * 2002-02-19 2003-08-28 Boehringer Ingelheim Pharma Verfahren zur Herstellung eines Pulverinhalativums enthaltend ein Salz des CGRP-Antagonisten BIBN4096
DE10207026A1 (de) * 2002-02-20 2003-08-28 Boehringer Ingelheim Kg Pulverinhalativum, enthaltend den CGRP-Antagonisten BIBN4096 und Verfahren zu dessen Herstellung
DE10338402A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sprühgetrocknetes, amorphes BIBN 4096, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum
DE10338403A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierung, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyrindinyl)-piperazin, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum
DE10338407A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Inhalationspulver enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin

Also Published As

Publication number Publication date
EP1658051A1 (fr) 2006-05-24
UY28474A1 (es) 2005-03-31
WO2005018609A1 (fr) 2005-03-03
JP2007502790A (ja) 2007-02-15
DE10338399A1 (de) 2005-03-17

Similar Documents

Publication Publication Date Title
US20050147568A1 (en) Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them
EP1734938B1 (fr) Micro-particules a base d'insuline et hautement inhalables
US20080038357A1 (en) Inhalation Powder Containing the CGRP antagonist BIBN4096 and Process for the Preparation Thereof
US20050043247A1 (en) Spray-dried amorphous BIBN 4096, process for preparing and the use thereof as inhalative
CA2536047A1 (fr) Bibn 4096 amorphe seche par pulverisation, procede de production dudit compose ainsi que son utilisation en tant que substance a inhaler
JP4384503B2 (ja) レボドパの肺送達
JP2007502789A6 (ja) 噴霧乾燥された無定形ｂｉｂｎ４０９６、その調製方法及び吸入剤としてのその使用
JP4085064B2 (ja) Ｃｇｒｐ拮抗剤ｂｉｂｎ４０９６の塩を含有する吸入粉末の調製方法
CN112040950A (zh) 治疗特发性肺纤维化的方法和组合物
US20060039985A1 (en) Methotrexate compositions
TW581681B (en) Liquid crystal forms of cyclosporin
US20050042178A1 (en) Microparticles containing the CGRP-antagonist 1-[N2-[3,5-dibrom-N-[[4-(3,4-dihydro-2(1H)-oxoquinazoline-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine, process for preparing and the use thereof as inhalation powder
CA2536048A1 (fr) Microparticules contenant l'antagoniste de cgrp 1-[n2-[3,5-dibromo-n-[[4-(3,4-dihydro-2(1h)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl)-piperazine, procede de production desdites particules ainsi que leur utilisation en tant que poudre d'inhalation
JP4085063B2 (ja) Ｃｇｒｐ拮抗剤ｂｉｂｎ４０９６を含有する吸入粉末及びその調製方法
JP2007502790A6 (ja) Ｃｇｒｐアンタゴニスト１−〔ｎ２−〔３，５−ジブロモ−ｎ−〔〔４−（３，４−ジヒドロ−２（１ｈ）−オキソキナゾリン−３−イル）−１−ピペリジニル〕カルボニル〕−ｄ−チロシル〕−ｌ−リシル〕−４−（４−ピリジニル）−ピペラジンを含む微粒子、その調製方法及び吸入粉末としてのその使用
CA2536053A1 (fr) Composition pulverulente contenant l'antagoniste cgrp 1-(n2-(3,5-dibromo-n-(4-(3,4-dihydro-2(1h)-oxoquinazolin-3-yl)- 1-piperidinyl)carbonyl)-d-tyrosyl)-l-lysyl)-4-(4-pyridinyl)-piperazine
JP2007502792A6 (ja) Ｃｇｒｐアンタゴニスト１−［ｎ２−［３，５−ジブロモ−ｎ−［［４−（３，４−ジヒドロ−２（１ｈ）−オキソキナゾリン−３−イル）−１−ピペリジニル］カルボニル］−ｄ−チロシル］−ｌ−リシル］−４−（４−ピリジニル）−ピペラジンを含有する粉末製剤、その吸入粉末としての製造方法及び使用
US20050042180A1 (en) Powder formulation containing the CGRP antagonist 1 [N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2 (1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin, process for preparing and the use thereof as inhalation powder
US20060222599A1 (en) Inhalative powder formulations containing the CGRP-antagonist 1 [N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine
JP2007502791A (ja) Ｃｇｒｐアンタゴニスト１−〔ｎ２−〔３，５−ジブロモ−ｎ−〔〔４−（３，４−ジヒドロ−２（１ｈ）−オキソキナゾリン−３−イル）−１−ピペリジニル〕カルボニル〕−ｄ−チロシル〕−ｌ−リシル〕−４−（４−ピリジニル）−ピペラジンを含む新規吸入粉末製剤
CN116744906A (zh) 用于制造包含伏立康唑的可吸入粉末的方法
KR20180052566A (ko) 폐 전달용 트립탄 분말

Legal Events

Date Code Title Description
FZDE Dead